134.17

0.08% -0.11

Pre-market: 135.98 1.81 +1.35%

Apogee Therapeutics Inc (APGE)

Overview News Price History Financials Discussions Forecast

Apogee Therapeutics Inc stock is traded at $134.17, with a volume of 949.70K. It is down -0.08% in the last 24 hours and up +1.22% over the past month. Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

Previous Close:

$134.28

Open:

$134.31

24h Volume:

949.70K

Relative Volume:

0.39

Market Cap:

$10.15B

Revenue:

Net Income/Loss:

$-274.62M

P/E Ratio:

-31.00

EPS:

-4.3278

Net Cash Flow:

$-235.37M

1W Performance:

-0.02%

1M Performance:

+1.22%

6M Performance:

+89.80%

1Y Performance:

+238.30%

1-Day Range:

$134.06

$134.35

1-Week Range:

$134.02

$134.46

52-Week Range:

$34.34

$134.46

Apogee Therapeutics Inc Stock (APGE) Company Profile

Name

Apogee Therapeutics Inc

Sector

Healthcare (1076)

Industry

Biotechnology (602)

Phone

650-394-5230

Address

221 CRESCENT ST., WALTHAM

Employee

261

Twitter

Next Earnings Date

2026-08-10

Latest SEC Filings

APGE's Discussions on Twitter

Compare APGE vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
APGE Apogee Therapeutics Inc	134.17	10.16B	0	-274.62M	-235.37M	-4.3278
VRTX Vertex Pharmaceuticals Inc	490.39	121.57B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	695.18	69.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	872.23	55.61B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	183.86	39.98B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	288.41	37.17B	4.29B	577.22M	641.34M	4.2086

Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-18-26	Initiated	Truist	Hold
Jan-22-26	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jan-07-26	Initiated	Wolfe Research	Peer Perform
Dec-17-25	Initiated	Stephens	Overweight
Dec-10-25	Initiated	Deutsche Bank	Buy
Nov-03-25	Initiated	Craig Hallum	Buy
Oct-21-25	Initiated	Mizuho	Outperform
Sep-25-25	Initiated	RBC Capital Mkts	Outperform
Jul-07-25	Reiterated	BTIG Research	Buy
Mar-13-25	Initiated	Citigroup	Buy
Nov-25-24	Initiated	Canaccord Genuity	Buy
May-10-24	Initiated	BofA Securities	Buy
Dec-20-23	Initiated	BTIG Research	Buy
Aug-08-23	Initiated	Guggenheim	Buy
Aug-08-23	Initiated	Jefferies	Buy
Aug-08-23	Initiated	Stifel	Buy
Aug-08-23	Initiated	TD Cowen	Outperform
Aug-08-23	Initiated	Wedbush	Outperform

View All

Apogee Therapeutics Inc Stock (APGE) Latest News

Jul 28, 2026

Is Apogee Therapeutics Inc. (APGE) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Jul 28, 2026

APGE|Apogee Therapeutics Inc|Price:134.310|Chg%:+0.030 - TradingKey

Jul 28, 2026

Jul 27, 2026